Compare Altria Group Inc (MO) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Sanofi SA — how do they compare? Altria Group Inc trades at $74.53 (market cap $124.67B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Altria Group Inc is the larger of the two by market cap, and Altria Group Inc pays the higher dividend (5.68%). Which is the better fit depends on your goals.
| MO | SNY | |
|---|---|---|
Market Cap | $124.67B | $104.83B |
Sector | Consumer Staples | Health |
52-Week High | $74.66 | $52.34 |
52-Week Low | $54.72 | $41.33 |
Enterprise Value | $145.75B | $121.32B |
Dividend Yield | 5.68% | 5.5% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
